ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with…Read More
You might also be interested in reading DraftKings kills NFT business, citing 'legal developments’.